- Home
- ALNY vs KR Comparison
ALNY vs KR Comparison
Compare ALNY & KR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALNY | KR |
|---|---|---|
| Founded | 2002 | 1883 |
| Country | United States | United States |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Food Chains |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9B | 37.1B |
| IPO Year | 2004 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ALNY | KR |
|---|---|---|
| Price | $270.80 | $56.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 12 |
| Target Price | ★ $471.00 | $74.25 |
| AVG Volume (30 Days) | 1.5M | ★ 7.4M |
| Earning Date | 04-30-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 2.09% |
| EPS Growth | ★ 206.88 | N/A |
| EPS | ★ 2.33 | 1.46 |
| Revenue | $1,037,418,000.00 | ★ $147,642,000,000.00 |
| Revenue This Year | $52.67 | $4.39 |
| Revenue Next Year | $31.48 | $2.30 |
| P/E Ratio | $116.64 | ★ $38.95 |
| Revenue Growth | ★ 22.88 | 0.35 |
| 52 Week Low | $262.21 | $54.15 |
| 52 Week High | $495.55 | $76.58 |
Technical Indicators
Market Signals| Indicator | ALNY | KR |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 41.90 |
| Support Level | N/A | $55.33 |
| Resistance Level | $318.35 | $64.44 |
| Average True Range (ATR) | 15.92 | 1.52 |
| MACD | -3.02 | 0.02 |
| Stochastic Oscillator | 8.17 | 30.69 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
About KR Kroger Company (The)
Founded in 1883, Kroger is the largest pure-play supermarket operator in the United States, operating roughly 2,700 stores across more than 30 banners. Kroger's business is primarily grocery-led (roughly 78% of sales), spanning fresh food and private-label offerings, complemented by fuel centers (9%) and pharmacies (12%). The firm also generates income from advertising, data analytics, and manufacturing.